Who Supplies Melatonin to India from BULGARIA

Importing finished pharmaceutical formulations containing melatonin into India requires compliance with the Drugs and Cosmetics Act, 1940, and associated rules. The Central Drugs Standard Control Organisation (CDSCO) mandates that all imported drugs be registered and approved. For melatonin formulations under HS Code 30049099, the importer must obtain a valid Drug Import License from the Directorate General of Foreign Trade (DGFT). Additionally, the manufacturer must provide a Certificate of Pharmaceutical Product (CoPP) and a Free Sale Certificate. The registration process typically takes 6 to 12 months, depending on the completeness of the submitted documentation. Importers should ensure that the melatonin formulations meet the standards set by the Indian Pharmacopoeia.

Upon arrival in India, each batch of imported melatonin formulations must undergo quality testing at a CDSCO-approved laboratory. The importer is required to submit a Certificate of Analysis (CoA) for each batch, demonstrating compliance with Indian Pharmacopoeia standards. Stability data, particularly for ICH Zone IV conditions, must be provided to ensure the product's efficacy and safety under Indian climatic conditions. Customs drug inspectors conduct port inspections to verify the authenticity of the documentation and the quality of the products. Any discrepancies or failures in quality testing can lead to delays, rejections, or destruction of the consignment.

Between 2024 and 2026, the CDSCO has implemented stricter regulations for the import of pharmaceutical formulations, including melatonin. The introduction of the Production Linked Incentive (PLI) scheme has incentivized domestic manufacturing, leading to a reduction in the import of certain formulations. However, melatonin formulations are not currently covered under the PLI scheme, maintaining their import viability. Bilateral agreements between India and Bulgaria have facilitated smoother trade relations, with mutual recognition of Good Manufacturing Practices (GMP) standards, thereby expediting the approval process for Bulgarian manufacturers.

India imports finished melatonin formulations primarily due to the demand for patented and branded products not manufactured domestically. Specific dosage forms, such as extended-release tablets and liquid formulations, are often sourced from international markets to meet consumer preferences. Domestic capacity for melatonin production is limited, leading to a dependency on imports to fulfill market needs. The Indian market for melatonin formulations is valued at approximately $9.4 million, with 116 exporters supplying to 51 countries.

The Basic Customs Duty (BCD) for melatonin formulations under HS Code 30049099 is 10%. An additional Social Welfare Surcharge (SWS) of 10% is levied on the BCD, resulting in a total duty of 20%. The Integrated Goods and Services Tax (IGST) applicable is 12%, calculated on the sum of the CIF (Cost, Insurance, and Freight) value plus the total duty. There are no additional duties such as the National Calamity Contingent Duty (NCCD) or Health Cess for this product category. Importers should account for these duties when calculating the total landed cost of the product.

India sources melatonin formulations from Bulgaria due to the competitive advantages offered by Bulgarian manufacturers, including adherence to international quality standards and the ability to supply specialized dosage forms not readily available domestically. Bulgaria's share in India's melatonin import market is approximately 0.02%, with other major suppliers being China, Germany, and the United States. The preference for Bulgarian products is attributed to their consistent quality and compliance with regulatory requirements, which are crucial for the Indian market.

India imports melatonin formulations from Bulgaria due to the availability of specialized dosage forms and patented products not manufactured domestically. Bulgarian manufacturers offer high-quality melatonin tablets and capsules that meet international standards, fulfilling specific market needs in India. The ability to supply these specialized formulations makes Bulgaria a preferred sourcing destination for Indian importers.

When compared to other sources like China, Germany, and the United States, Bulgaria offers competitive pricing and consistent quality. While China may offer lower prices, concerns about quality and regulatory compliance can be a deterrent. Germany and the United States provide high-quality products but at higher costs. Bulgaria's unique advantage lies in its ability to balance quality and cost-effectiveness, making it an attractive option for Indian importers.

Potential risks for Indian importers include currency fluctuations, regulatory changes in Bulgaria, and shipping disruptions. To mitigate these risks, importers should establish strong relationships with Bulgarian suppliers, monitor currency exchange rates, and maintain adequate inventory levels. There have been no significant shortages reported in the supply of melatonin formulations from Bulgaria to India in recent years.

1. 1Dual-Sourcing: Engage with multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain buffer stock to manage supply chain disruptions.
3. 3Payment Terms: Negotiate favorable terms such as Letter of Credit (LC) to secure transactions.
4. 4Supplier Qualification: Conduct thorough due diligence to ensure compliance with regulatory standards.
5. 5Regulatory Compliance: Stay updated on changes in import regulations and ensure all documentation is in order.

1. 1DGFT Import License: Obtain a valid license from the Directorate General of Foreign Trade.
2. 2CDSCO Registration: Register the product with the Central Drugs Standard Control Organisation.
3. 3Form 40/41: Submit the necessary forms for drug importation.
4. 4NOC: Secure a No Objection Certificate from the relevant authorities.
5. 5Customs Broker